Gut and Liver 2007; 1(2): 151-158 https://doi.org/10.5009/gnl.2007.1.2.151 Prevention by Lamivudine of Hepatocellular Carcinoma in Patients Infected with Hepatitis B Virus
Author Information
Heon Ju Lee, Ryul Eun, Byung Ik Jang, and Tae Nyeun KimHeon Ju Lee, Ryul Eun, Byung Ik Jang, and Tae Nyeun Kim
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea

Heon Ju Lee
© The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. All rights reserved.

Abstract
Background/Aims: This study evaluated the prevention by lamivudine of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. Methods: Lamivudine therapy was administered to 879 of the 2,511 patients who satisfied our analysis inclusion criteria. A Cox regression model revealed that four factors increased the prevalence of HCC: gender (females; OR=0.53, p=0.006), age (≥40 years; OR=4.64, p<0.001), platelet count (≥100×103/mm3; OR=0.35, p<0.001), and alcohol consumption (≥80 g/day; OR= 1.79, p=0.004). Five hundred and eighty-nine patients in the lamivudine-treated group and 589 patients in the control group were selected for a matched case- control study. The mean follow-up periods were 2.8 and 5.1 years in the lamivudine-treated and control groups, respectively. Results: HCC occurred in 10 patients (1.7%) of the lamivudine group, with an incidence rate of 0.61% patients/year, and in 65 patients (11.0%) of the control group, with an incidence rate of 2.16% patients/year. The cumulative incidence of HCC was lower in the lamivudine group than in the control group (p=0.0117, log-rank test). Conclusions: Lamivudine can reduce the incidence of HCC in patients suffering from chronic hepatitis B. (Gut and Liver 2007;1:151-158)
Keywords: Lamivudine; Chronic hepatitis B; Hepatocellular carcinoma; Prevention
Abstract
Background/Aims: This study evaluated the prevention by lamivudine of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. Methods: Lamivudine therapy was administered to 879 of the 2,511 patients who satisfied our analysis inclusion criteria. A Cox regression model revealed that four factors increased the prevalence of HCC: gender (females; OR=0.53, p=0.006), age (≥40 years; OR=4.64, p<0.001), platelet count (≥100×103/mm3; OR=0.35, p<0.001), and alcohol consumption (≥80 g/day; OR= 1.79, p=0.004). Five hundred and eighty-nine patients in the lamivudine-treated group and 589 patients in the control group were selected for a matched case- control study. The mean follow-up periods were 2.8 and 5.1 years in the lamivudine-treated and control groups, respectively. Results: HCC occurred in 10 patients (1.7%) of the lamivudine group, with an incidence rate of 0.61% patients/year, and in 65 patients (11.0%) of the control group, with an incidence rate of 2.16% patients/year. The cumulative incidence of HCC was lower in the lamivudine group than in the control group (p=0.0117, log-rank test). Conclusions: Lamivudine can reduce the incidence of HCC in patients suffering from chronic hepatitis B. (Gut and Liver 2007;1:151-158)
Keywords: Lamivudine; Chronic hepatitis B; Hepatocellular carcinoma; Prevention
Search for
Services
Archives